<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/DDD14154-81FB-417E-81AA-AAEA066ECA04"><gtr:id>DDD14154-81FB-417E-81AA-AAEA066ECA04</gtr:id><gtr:name>The Wellcome Trust  Sanger Institute</gtr:name><gtr:address><gtr:line1>Wellcome Trust Genome Campus</gtr:line1><gtr:line2>Hinxton</gtr:line2><gtr:postCode>CB10 1SA</gtr:postCode><gtr:region>East of England</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:department>Haematology</gtr:department><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/DDD14154-81FB-417E-81AA-AAEA066ECA04"><gtr:id>DDD14154-81FB-417E-81AA-AAEA066ECA04</gtr:id><gtr:name>The Wellcome Trust  Sanger Institute</gtr:name><gtr:address><gtr:line1>Wellcome Trust Genome Campus</gtr:line1><gtr:line2>Hinxton</gtr:line2><gtr:postCode>CB10 1SA</gtr:postCode><gtr:region>East of England</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/748DF1D8-D39E-4047-B5CC-0D6864CA4C1A"><gtr:id>748DF1D8-D39E-4047-B5CC-0D6864CA4C1A</gtr:id><gtr:firstName>Brian</gtr:firstName><gtr:otherNames>James</gtr:otherNames><gtr:surname>Huntly</gtr:surname><gtr:orcidId>0000-0003-0312-161X</gtr:orcidId><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G116%2F187"><gtr:id>E940DE39-14FD-4B6E-90DD-0DE81192598B</gtr:id><gtr:title>Self-renewal in Leukaemia Stem Cells: identification of novel self-renewal pathways and the role of homeobox proteins</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Fellowship</gtr:grantCategory><gtr:grantReference>G116/187</gtr:grantReference><gtr:abstractText>Recent research in leukaemia and other cancers suggests that a critical subpopulation of cells within the cancer control the growth and spread of these tumours, the so called cancer stem cells A likely explanation for the lack of effect of many cancer therapies or the recurrence of tumours following therapy is that current drugs do not affect this important population of cells. 

Using leukaemia as a model for all cancers, this proposal aims to identify the mechanisms which control the renewal of these cancer stem cells and therefore the ability of the cancers to continue growing. 

This research should improve our understanding of the mechanisms of cancer growth and help to identify new therapies to target these critical cells and improve the treatment of cancer patients</gtr:abstractText><gtr:technicalSummary>Many cancers appear to be dependent upon a small proportion of cancer stem cells for their continued growth and propagation. Leukaemia Stem Cells (LSC) were the first such cells to be identified. It is likely that LSC are the most critical target for the treatment of leukaemia, and are ultimately the basis for relapsed disease in patients who respond to treatment. It is therefore of the utmost importance to understand the fundamental biological properties of normal and leukaemic stem cells, including molecular mechanisms of self-renewal. These insights may allow for development of therapies that differentially target normal and leukaemic stem cells. In addition, an understanding of the LSC may provide important insights into cancer stem cells in solid tumours. However, the origins and biology of LSC remains obscure, in part due to our incomplete understanding of normal haematopoietic stem cell (HSC) biology. The normal and malignant haematopoietic systems are well characterised in both mice and humans, are easily amenable to study, and provide a powerful platform to study leukaemic stem cells. I plan to further dissect the molecular mechanisms of self-renewal in LSC building upon my recent work in Boston. 

I have shown that the leukaemia associated oncogene MOZ-TIF2 may confer properties of self-renewal to committed haematopoietic progenitors which inherently lack these properties. I further plan to investigate whether this is a general ability of leukaemia associated oncogenes or specific only to some oncogenes. Point mutants of MOZ-TIF2 do not confer properties of self-renewal to committed progenitors. Utilising differences in gene expression between progenitors expressing mutant and wild type MOZ-TIF2, this system will provide a powerful platform for the identification of genetic programmes which mediate self-renewal in LSC and possibly normal stem cells. This discovery based approach will determine candidate self-renewal genes which will be functionally validated with in vitro and in vivo assays of self-renewal. Functionally validated candidates may then be taken forward to generate gene targeted mouse models for further study as long-term objectives of the proposal.

In a complementary approach I plan to investigate a known pathway of self-renewal, the HOX gene pathway. Using a conditional knock-out mouse model I am currently generating I will initiate a detailed characterisation of a novel homeodomain protein, CDX4, as a master regulator of expression of HOX family members that are known to play critical roles in haematopoietic development, leukaemogenesis and self-renewal.</gtr:technicalSummary><gtr:fund><gtr:end>2010-10-09</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2005-10-10</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>1259674</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Cambridge</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Gurdon Institute</gtr:department><gtr:description>Epigenetics of haematological malignancies</gtr:description><gtr:id>E3BD54E7-22E3-4057-AB53-A4D3C8F8ED28</gtr:id><gtr:impact>Dawson et al Nature 478(7370):529-33
PMID 21964340</gtr:impact><gtr:outcomeId>HRFiNkdPTct-1</gtr:outcomeId><gtr:partnerContribution>Expertise in chromatin biology</gtr:partnerContribution><gtr:piContribution>Expertise in cellular and animal models of leukaemia
Expertise in medical treatment of leukaemia</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>The Wellcome Trust Sanger Institute</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Mouse models of acute myeloid leukaemia</gtr:description><gtr:id>4E46F4DA-CC6D-427A-BFA5-1651ECA08923</gtr:id><gtr:impact>Obtained &amp;pound;620,000 grant from Leukaemia and Lymphoma Research to pursue research</gtr:impact><gtr:outcomeId>eAQVxP7zVSr-1</gtr:outcomeId><gtr:partnerContribution>Expertise in generation of mouse models</gtr:partnerContribution><gtr:piContribution>Intellectual plans for models and expertise in mouse modeling and studies to determine mechanisms of disease</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Times Science Festival Cheltenham</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:id>626FB9DC-4938-4B50-AF0A-438A2E5F832E</gtr:id><gtr:impact>200 people attended brief presentations and discussions abot the subject of cancer stem cells. I was a presenter and panel member for these discussions

Excellent feedback reported to the organisers. Reported on CRUK website</gtr:impact><gtr:outcomeId>nECFz8axZME</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Schools visit</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:id>ECF80538-B20F-4EBB-BACF-EC110FE6B637</gtr:id><gtr:impact>Discussion to pupils re &amp;quot;stem cells and canccer stem cells&amp;quot;

Highlight the possibilities of regenerative medicine and improvements in cancer therapeutics</gtr:impact><gtr:outcomeId>64BC7607E92</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2008</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>830000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Wellcome trust intermediate fellowship</gtr:description><gtr:end>2014-02-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:id>E1BA480F-ABB2-4B11-9146-8500113AC034</gtr:id><gtr:outcomeId>040771516E90</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2010-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>215000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>KKLF Project Grant</gtr:description><gtr:end>2012-12-02</gtr:end><gtr:fundingOrg>The Kay Kendall Leukaemia Fund (KKLF)</gtr:fundingOrg><gtr:id>FDF57D8B-E57D-49C7-9A8F-68B231AF1161</gtr:id><gtr:outcomeId>C4EB32D1D640</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>230000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Leukemia and Lymphoma Research project grant</gtr:description><gtr:end>2013-09-02</gtr:end><gtr:fundingOrg>Leukaemia and Lymphoma Research</gtr:fundingOrg><gtr:id>2E4581C3-85F6-475F-9F33-D2AC32C3504C</gtr:id><gtr:outcomeId>riiRgJoNdV20</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2010-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>200000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>CRUK Project Grant</gtr:description><gtr:end>2010-07-02</gtr:end><gtr:fundingOrg>Cancer Research UK</gtr:fundingOrg><gtr:id>2ED47A44-90D9-409A-AC9F-7196AD050226</gtr:id><gtr:outcomeId>BA3E18163220</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2007-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>230000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Wellcome trust Research Training Fellowship</gtr:description><gtr:end>2013-09-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:id>E2E3F291-F998-451C-9A25-7DA1B85FAFA7</gtr:id><gtr:outcomeId>6AD8D8691740</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2010-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>620000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Leukaemia and Lymphoma Research (LLR) specialist programme grants</gtr:description><gtr:end>2015-01-02</gtr:end><gtr:fundingOrg>Leukaemia and Lymphoma Research</gtr:fundingOrg><gtr:id>BDCC2074-0F99-4AE1-AE78-3791F6026747</gtr:id><gtr:outcomeId>oPQt6atz1Xq0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-02-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>170000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>KKLF Project Grant</gtr:description><gtr:end>2009-09-02</gtr:end><gtr:fundingOrg>The Kay Kendall Leukaemia Fund (KKLF)</gtr:fundingOrg><gtr:id>31D1767A-550E-4E0B-BF47-A14DB40C5BD6</gtr:id><gtr:outcomeId>AFC80CC4CC10</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2006-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>700000</gtr:amountPounds><gtr:country>Canada</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Leukemia and Lymphoma Society of Canada</gtr:department><gtr:description>LLS Marshall A. Lichtman Specialized Center of Research (SCOR) program</gtr:description><gtr:end>2011-09-02</gtr:end><gtr:fundingOrg>The Leukemia &amp; Lymphoma Society</gtr:fundingOrg><gtr:id>959C8606-0518-41E3-A172-CAA86F12445F</gtr:id><gtr:outcomeId>98FC677D1580</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2006-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>700000</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>LLS Marshall A. Lichtman Specialized Center of Research (SCOR) program</gtr:description><gtr:end>2016-09-02</gtr:end><gtr:fundingOrg>The Leukemia &amp; Lymphoma Society</gtr:fundingOrg><gtr:id>E3ACFA8A-BAAB-4E0E-A94C-99CE6F1429B2</gtr:id><gtr:outcomeId>iS36Kpfc2WB0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>230000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>CRUK Project Grant</gtr:description><gtr:end>2011-10-02</gtr:end><gtr:fundingOrg>Cancer Research UK</gtr:fundingOrg><gtr:id>77E85E63-3AB4-4D16-B675-50F6769BB69C</gtr:id><gtr:outcomeId>C5D16991B780</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2008-11-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>230000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>KKLF Clinical Research Fellowship</gtr:description><gtr:end>2012-04-02</gtr:end><gtr:fundingOrg>The Kay Kendall Leukaemia Fund (KKLF)</gtr:fundingOrg><gtr:id>A96C07B0-D4AF-42E5-8301-297120600B2A</gtr:id><gtr:outcomeId>B351DA6178B0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2008-07-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>NCRI Chronic Myeloid Leukaemia (CML) working party</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>4F718FD7-715F-48BD-A0D9-6E20CD1B7CDB</gtr:id><gtr:impact>To define and implement treatment policy for the UK clinical community in CML. To decide upon the nature of national trials in this disease</gtr:impact><gtr:outcomeId>Av4DwFq7j3R</gtr:outcomeId><gtr:type>Membership of a guideline committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>NICE scoping committee</gtr:description><gtr:geographicReach>UK</gtr:geographicReach><gtr:id>58C543A1-68DD-4A1B-BBEC-6DF23B4F749B</gtr:id><gtr:impact>Member of a scoping committee to decide upon the appropriateness of a novel therapy for consideratin by NICE.</gtr:impact><gtr:outcomeId>eFCUi52CB55</gtr:outcomeId><gtr:type>Participation in a national consultation</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>During my MRC funded PhD (MRC CTF grant number G84/ 5101) I demonstrated the presence and prognostic significance of deletions of the derivative chromosome 9 accompanying the Philadelphia (Ph) translocation (between Ch 9 and 22) in chronic myeloid leukaemia. Patients who demonstrate der9 deletions have a shorter survival by comparison with those who do not. In light of this finding manufacturers of fluorescence in situ hybridisation (FISH) probes for the documentation of the Ph chromosome have altered there probe sets to allow the concommitant detection of deletions and these are routinely documented worldwide.</gtr:description><gtr:id>07C51D5D-F6DD-4D42-9752-CD090C0511AF</gtr:id><gtr:impact>New prognostic tool for CML patients</gtr:impact><gtr:outcomeId>B2A0D3C0E24</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Deletions of Chromosome 9 in CML</gtr:title><gtr:type>Physiological assessment or outcome measure</gtr:type><gtr:yearFirstProvided>2006</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>In collaboration with my former lab I have generated a conditional knockout mouse for the Cdx4 locus, which has been used to probe the requirements of this gene and its putative control of Hox genes in the process of haematopopiesis</gtr:description><gtr:id>D6CA56F7-1A3F-4D7A-984A-A9D5327CB059</gtr:id><gtr:impact>In work in submission, it has demonstrated a high degree of functional redundancy between the mammalian Cdx genes for haematopoiesis and has also highlighted significant differences between mammalian and zebrafish haematopoietic systems in their requirement for Cdx proteins</gtr:impact><gtr:outcomeId>446FA0834AF</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Conditional Cdx4 knockout mouse</gtr:title><gtr:type>Model of mechanisms or symptoms - mammalian in vivo</gtr:type><gtr:yearFirstProvided>2008</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>5901D0F5-1672-4EE4-BD9F-0F0EE525A47C</gtr:id><gtr:title>Reprogramming of T cells to natural killer-like cells upon Bcl11b deletion.</gtr:title><gtr:parentPublicationTitle>Science (New York, N.Y.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/46346cbf44e848fbe06e531688e1a872"><gtr:id>46346cbf44e848fbe06e531688e1a872</gtr:id><gtr:otherNames>Li P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0036-8075</gtr:issn><gtr:outcomeId>AzrzLnFn8sb</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9F635FEB-37FF-47B2-910F-B313D0ABBBA0</gtr:id><gtr:title>JAK2 V617F impairs hematopoietic stem cell function in a conditional knock-in mouse model of JAK2 V617F-positive essential thrombocythemia.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ad7968d586527c1fd3f76aeabf35ac38"><gtr:id>ad7968d586527c1fd3f76aeabf35ac38</gtr:id><gtr:otherNames>Li J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>eLqYQDxbvYj</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6996D7F8-F42D-43C6-A5A4-B33DEAE047D3</gtr:id><gtr:title>Cdx4 is dispensable for murine adult hematopoietic stem cells but promotes MLL-AF9-mediated leukemogenesis.</gtr:title><gtr:parentPublicationTitle>Haematologica</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f7d6e369d88c2e1e9c2407f551a66a63"><gtr:id>f7d6e369d88c2e1e9c2407f551a66a63</gtr:id><gtr:otherNames>Koo S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0390-6078</gtr:issn><gtr:outcomeId>FJiMogxcxzo</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>44273AB7-9C87-43B1-A38E-11E67F2E975B</gtr:id><gtr:title>A previously unrecognized promoter of LMO2 forms part of a transcriptional regulatory circuit mediating LMO2 expression in a subset of T-acute lymphoblastic leukaemia patients.</gtr:title><gtr:parentPublicationTitle>Oncogene</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8f1c42ed2a59e163cc9b5bd0b639352a"><gtr:id>8f1c42ed2a59e163cc9b5bd0b639352a</gtr:id><gtr:otherNames>Oram SH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0950-9232</gtr:issn><gtr:outcomeId>dxfoXRYcLpA</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FAB20C33-9E62-4691-AA94-5562C168FF58</gtr:id><gtr:title>The transcriptional coactivator Cbp regulates self-renewal and differentiation in adult hematopoietic stem cells.</gtr:title><gtr:parentPublicationTitle>Molecular and cellular biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b542108a7291c98a4946e49f43fecfc5"><gtr:id>b542108a7291c98a4946e49f43fecfc5</gtr:id><gtr:otherNames>Chan WI</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0270-7306</gtr:issn><gtr:outcomeId>eSmG1NmVsVM</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>60166447-5EE8-4C49-98E7-155A839E76CC</gtr:id><gtr:title>Acute myeloid leukemia: leukemia stem cells write a prognostic signature.</gtr:title><gtr:parentPublicationTitle>Stem cell research &amp; therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a54e35ad197b1a63030dc8a4ee290a5d"><gtr:id>a54e35ad197b1a63030dc8a4ee290a5d</gtr:id><gtr:otherNames>Gudgin EJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1757-6512</gtr:issn><gtr:outcomeId>J8Ltq6ZuFdK</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6672E364-D341-470E-9F12-13494B8C964F</gtr:id><gtr:title>Common and overlapping oncogenic pathways contribute to the evolution of acute myeloid leukemias.</gtr:title><gtr:parentPublicationTitle>Cancer research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5eb100701341d853b3d08917df822996"><gtr:id>5eb100701341d853b3d08917df822996</gtr:id><gtr:otherNames>Kvinlaug BT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0008-5472</gtr:issn><gtr:outcomeId>rfrtkt3D34b</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>468AB201-43FB-48E2-B896-597F2F9B6088</gtr:id><gtr:title>Effects of the JAK2 mutation on the hematopoietic stem and progenitor compartment in human myeloproliferative neoplasms.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7182447178e6d6bf50de9bca38502e7e"><gtr:id>7182447178e6d6bf50de9bca38502e7e</gtr:id><gtr:otherNames>Anand S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>NBMwznHkH26</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5FF70AF5-1D39-4AAF-9B23-A21DD0161E6B</gtr:id><gtr:title>FoxOs are critical mediators of hematopoietic stem cell resistance to physiologic oxidative stress.</gtr:title><gtr:parentPublicationTitle>Cell</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7b988944c65dcd0eebf9373e66c79f88"><gtr:id>7b988944c65dcd0eebf9373e66c79f88</gtr:id><gtr:otherNames>Tothova Z</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0092-8674</gtr:issn><gtr:outcomeId>5AB5C10CFCF</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9B193FC7-857D-4855-820A-81471E983A32</gtr:id><gtr:title>The homeobox gene CDX2 is aberrantly expressed in most cases of acute myeloid leukemia and promotes leukemogenesis.</gtr:title><gtr:parentPublicationTitle>The Journal of clinical investigation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/44dc698d146465b58dbbc9e13ac884c6"><gtr:id>44dc698d146465b58dbbc9e13ac884c6</gtr:id><gtr:otherNames>Scholl C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0021-9738</gtr:issn><gtr:outcomeId>AF94274C751</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C804578D-16BE-4EEF-8A2A-8F76D8F16348</gtr:id><gtr:title>Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia.</gtr:title><gtr:parentPublicationTitle>Nature</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1dd8c770b8b61743ce0f7fb94dc40087"><gtr:id>1dd8c770b8b61743ce0f7fb94dc40087</gtr:id><gtr:otherNames>Dawson MA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0028-0836</gtr:issn><gtr:outcomeId>TmKK8rCqj9n</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C9B5E00E-B100-42EA-8369-C29D3D24A660</gtr:id><gtr:title>Molecular basis of histone H3K36me3 recognition by the PWWP domain of Brpf1.</gtr:title><gtr:parentPublicationTitle>Nature structural &amp; molecular biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/254b59b469274ae879ceb36cdb1fa0d1"><gtr:id>254b59b469274ae879ceb36cdb1fa0d1</gtr:id><gtr:otherNames>Vezzoli A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1545-9985</gtr:issn><gtr:outcomeId>JbYGpzjM2H6</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1EB691DE-2AB9-4C63-B91D-35036A318AA4</gtr:id><gtr:title>HOX gene regulation in acute myeloid leukemia: CDX marks the spot?</gtr:title><gtr:parentPublicationTitle>Cell cycle (Georgetown, Tex.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4a3f11c4ca64a54d9a9a0b6ecfc46ca1"><gtr:id>4a3f11c4ca64a54d9a9a0b6ecfc46ca1</gtr:id><gtr:otherNames>Fr?hling S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1551-4005</gtr:issn><gtr:outcomeId>9561743FB2C</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4F6B3CFC-9F61-4C31-B6C6-26E877BD8F8D</gtr:id><gtr:title>Targeting cancer stem cells.</gtr:title><gtr:parentPublicationTitle>Expert opinion on therapeutic targets</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5eb100701341d853b3d08917df822996"><gtr:id>5eb100701341d853b3d08917df822996</gtr:id><gtr:otherNames>Kvinlaug BT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1472-8222</gtr:issn><gtr:outcomeId>127802BCB9A</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7024BC3F-B290-405B-9B86-F9F73DA7D496</gtr:id><gtr:title>Clonal diversity in the myeloproliferative neoplasms: independent origins of genetically distinct clones.</gtr:title><gtr:parentPublicationTitle>British journal of haematology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/296879fed7b3e8f45170a5046d8ad06e"><gtr:id>296879fed7b3e8f45170a5046d8ad06e</gtr:id><gtr:otherNames>Beer PA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0007-1048</gtr:issn><gtr:outcomeId>25718B2BE93</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7B4E953A-BD52-4DA3-941E-B01A79286D96</gtr:id><gtr:title>Modeling the evolution of ETV6-RUNX1-induced B-cell precursor acute lymphoblastic leukemia in mice.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bf9a4b415a8696967a5bf0e850388395"><gtr:id>bf9a4b415a8696967a5bf0e850388395</gtr:id><gtr:otherNames>van der Weyden L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>qZSs5sQyA33</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>01C9314A-18CB-42D0-A2E6-B883414F7A91</gtr:id><gtr:title>Inhibition of the Bcl-xL deamidation pathway in myeloproliferative disorders.</gtr:title><gtr:parentPublicationTitle>The New England journal of medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/eccd13f354b70009563e54621164e744"><gtr:id>eccd13f354b70009563e54621164e744</gtr:id><gtr:otherNames>Zhao R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0028-4793</gtr:issn><gtr:outcomeId>924DEB38B22</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>71DC183B-27AE-4221-8D68-8E01D2E0876E</gtr:id><gtr:title>FLT3 mutations confer enhanced proliferation and survival properties to multipotent progenitors in a murine model of chronic myelomonocytic leukemia.</gtr:title><gtr:parentPublicationTitle>Cancer cell</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ebd8c0877a282a7a0b9a64d9c93b5684"><gtr:id>ebd8c0877a282a7a0b9a64d9c93b5684</gtr:id><gtr:otherNames>Lee BH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1535-6108</gtr:issn><gtr:outcomeId>9B91C8B8039</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4BA45F3C-3622-46A8-B811-A4A1C899E7B9</gtr:id><gtr:title>Increased basal intracellular signaling patterns do not correlate with JAK2 genotype in human myeloproliferative neoplasms.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7182447178e6d6bf50de9bca38502e7e"><gtr:id>7182447178e6d6bf50de9bca38502e7e</gtr:id><gtr:otherNames>Anand S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>FtcyVuAEL1X</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2610B91E-194A-49E2-8830-6713D0F4962F</gtr:id><gtr:title>Leukemia stem cells in acute myeloid leukemia.</gtr:title><gtr:parentPublicationTitle>Seminars in oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b542108a7291c98a4946e49f43fecfc5"><gtr:id>b542108a7291c98a4946e49f43fecfc5</gtr:id><gtr:otherNames>Chan WI</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0093-7754</gtr:issn><gtr:outcomeId>A1C802730E3</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>61E90CCC-B7CF-477C-B6C3-8744D1F7436F</gtr:id><gtr:title>Genome-wide analysis of transcriptional reprogramming in mouse models of acute myeloid leukaemia.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/52574b01e525544e39f0eeeb846c20f9"><gtr:id>52574b01e525544e39f0eeeb846c20f9</gtr:id><gtr:otherNames>Bonadies N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>KarANmrXes7</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D9E4F456-284D-42E1-99E0-D5CBA7D3A6B2</gtr:id><gtr:title>Cdx4 dysregulates Hox gene expression and generates acute myeloid leukemia alone and in cooperation with Meis1a in a murine model.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ba93bf71e0a6d20ab09238624daefb8d"><gtr:id>ba93bf71e0a6d20ab09238624daefb8d</gtr:id><gtr:otherNames>Bansal D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>Rs1AFJE5mgn</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G116/187</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>7C58A707-1BF6-4573-A44F-30B271C80813</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Cancer</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>